血糖变异性是糖尿病合并急性冠脉综合征患者中期主要不良心脏事件的强独立预测因素
该研究纳入327例糖尿病合并急性冠脉综合征(ACS)患者,以住院期间血糖标准差评估血糖变异性(GV),平均随访16.9个月。结果显示GV>2.70 mmol/L是中期主要不良心脏事件(MACE)最强的独立预测因素(OR 2.21,95%CI 1.64-2.98,P<0.001)。
要点
- GV>2.70 mmol/L是糖尿病合并ACS患者中期MACE最强的独立预测因素。
- SYNTAX评分>34和LVEF<40%也是MACE的独立预测因素,GRACE评分>140则不是。
- 住院期间血糖标准差可用于识别糖尿病合并ACS后中期MACE高风险患者。
核心结论
- 血糖变异性(GV)>2.70 mmol/L是糖尿病合并ACS患者中期MACE最强的独立预测因素。
研究设计与样本
- GV以初始住院期间血糖标准差评估,记录新发心肌梗死、急性心力衰竭和心源性死亡等MACE。
主要发现
- 平均随访16.9个月期间,89例(27.2%)发生MACE。
- 随访期间24例(7.3%)死于心脏原因,35例(10.7%)新发心肌梗死,30例(9.2%)因急性心力衰竭住院。
- 多因素logistic回归显示GV>2.70 mmol/L的OR为2.21(95%CI 1.64-2.98;P<0.001)。
- SYNTAX评分>34的OR为1.88(95%CI 1.26-2.82;P=0.002)。
- LVEF<40%的OR为1.71(95%CI 1.14-2.54;P=0.009);GRACE评分>140的OR为1.07(95%CI 0.77-1.49;P=0.69)。
关键数值与推荐
- GV>2.70 mmol/L是中期MACE的独立预测因素(OR 2.21,95%CI 1.64-2.98;P<0.001)。
- SYNTAX评分>34是中期MACE的独立预测因素(OR 1.88,95%CI 1.26-2.82;P=0.002)。
- LVEF<40%是中期MACE的独立预测因素(OR 1.71,95%CI 1.14-2.54;P=0.009)。
- GRACE风险评分>140不是中期MACE的独立预测因素(OR 1.07,95%CI 0.77-1.49;P=0.69)。
临床怎么用
- 对糖尿病合并ACS患者,住院期间可监测血糖标准差以评估GV。
- GV>2.70 mmol/L提示中期MACE风险较高,可考虑加强随访和风险管理。
- 结合SYNTAX评分>34和LVEF<40%等指标综合评估中期MACE风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Acute glucose fluctuations are associated with hypoglycemia and are emerging risk factors for cardiovascular outcomes. However, the relationship between glycemic variability (GV) and the occurrence of midterm major cardiovascular events (MACE) in patients with diabetes remains unclear. This study investigated the prognostic value of GV in patients with diabetes and acute coronary syndrome (ACS). RESEARCH DESIGN AND METHODS: This study included consecutive patients with diabetes and ACS between January 2015 and November 2016. GV was assessed using SD during initial hospitalization. MACE, including new-onset myocardial infarction, acute heart failure, and cardiac death, were recorded. The predictive effects of GV on patient outcomes were analyzed with respect to baseline characteristics and cardiac status. RESULTS: A total of 327 patients with diabetes and ACS were enrolled. MACE occurred in 89 patients (27.2%) during a mean follow-up of 16.9 months. During follow-up, 24 patients (7.3%) died of cardiac causes, 35 (10.7%) had new-onset myocardial infarction, and 30 (9.2%) were hospitalized for acute heart failure. Multivariable logistic regression analysis showed that GV >2.70 mmol/L, a Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) score >34, and reduced left ventricular ejection fraction of <40% were independent predictors of MACE, with odds ratios (ORs) of 2.21 (95% CI 1.64-2.98; P < 0.001), 1.88 (1.26-2.82; P = 0.002), and 1.71 (1.14-2.54; P = 0.009), respectively, whereas a Global Registry of Acute Coronary Events (GRACE) risk score >140 was not (OR 1.07 [0.77-1.49]; P = 0.69). CONCLUSIONS: A GV cutoff value of >2.70 mmol/L was the strongest independent predictive factor for midterm MACE in patients with diabetes and ACS.
引用
- Gerbaud E, Darier R, Montaudon M, et al. Glycemic Variability Is a Powerful Independent Predictive Factor of Midterm Major Adverse Cardiac Events in Patients With Diabetes With Acute Coronary Syndrome. Diabetes Care. 2019. PMID: 30728222. doi:10.2337/dc18-2047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。